Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Greenbaum

Showing results (91-100 of 225) with videos related to

Pageof 23
Sort By:
Canadian Medical Association Journal|March 15, 1982
Control of asthmaJ Dolovich, F E Hargreave, W M Wilson, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1C J Greenbaum, D A Schatz, D Cuthbertson, et al.
Journal of Autoimmunity|December 29, 2005
Evaluation of leptin levels in subjects at risk for type 1 diabetesLisa K Gilliam, Richard A Jensen, Pam Yang, et al.
Genes and Immunity|June 22, 2018
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetesPeter S Linsley, Carla J Greenbaum, Mario Rosasco, et al.
Diabetes Care|February 28, 2015
The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose ToleranceWei Hao, Carla J Greenbaum, Jeffrey P Krischer, et al.
The Journal of Clinical Endocrinology and Metabolism|May 7, 2024
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 DiabetesStephan Pribitzer, Colin O'Rourke, Alyssa Ylescupidez, et al.
Diabetes Care|March 22, 2018
Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 DiabetesPolly J Bingley, Diane K Wherrett, Ann Shultz, et al.
Diabetes/Metabolism Research and Reviews|February 18, 2015
Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspectiveJennifer B Bollyky, Ping Xu, Atul J Butte, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 31, 1997
Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunityJ P McLaughlin, S Abrams, J Kantor, et al.
Journal of Diabetes Science and Technology|September 16, 2015
Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic ControllerRichard Mauseth, Sandra M Lord, Irl B Hirsch, et al.
Pageof 23

Showing results (91-100 of 225) with videos related to

Sort By:
Pageof 23
Canadian Medical Association Journal|March 15, 1982
Control of asthmaJ Dolovich, F E Hargreave, W M Wilson, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1C J Greenbaum, D A Schatz, D Cuthbertson, et al.
Journal of Autoimmunity|December 29, 2005
Evaluation of leptin levels in subjects at risk for type 1 diabetesLisa K Gilliam, Richard A Jensen, Pam Yang, et al.
Genes and Immunity|June 22, 2018
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetesPeter S Linsley, Carla J Greenbaum, Mario Rosasco, et al.
Diabetes Care|February 28, 2015
The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose ToleranceWei Hao, Carla J Greenbaum, Jeffrey P Krischer, et al.
The Journal of Clinical Endocrinology and Metabolism|May 7, 2024
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 DiabetesStephan Pribitzer, Colin O'Rourke, Alyssa Ylescupidez, et al.
Diabetes Care|March 22, 2018
Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 DiabetesPolly J Bingley, Diane K Wherrett, Ann Shultz, et al.
Diabetes/Metabolism Research and Reviews|February 18, 2015
Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspectiveJennifer B Bollyky, Ping Xu, Atul J Butte, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 31, 1997
Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunityJ P McLaughlin, S Abrams, J Kantor, et al.
Journal of Diabetes Science and Technology|September 16, 2015
Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic ControllerRichard Mauseth, Sandra M Lord, Irl B Hirsch, et al.
Pageof 23